Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sea buckthorn pulp oil (SBPO) is a bioactive lipid extracted from the fruit pulp of *Hippophae rhamnoides*, characterized by high concentrations of palmitoleic acid (omega-7), carotenoids, and tocopherols. In the context of inflammatory bowel disease (IBD), SBPO is researched for its potent anti-inflammatory and antioxidant properties. Recent breakthroughs have focused on enhancing its therapeutic efficacy through nanoemulsion formulations, such as those stabilized with sodium caseinate and Salecan β-glucan conjugates. These formulations are designed to overcome SBPO's inherent instability and bitterness while providing colon-targeted delivery. Mechanistically, SBPO nanoemulsions have demonstrated the ability to suppress pro-inflammatory cytokines, enhance antioxidant enzyme activity, restore gut microbial balance, and increase the production of beneficial short-chain fatty acids (SCFAs), thereby reducing clinical symptoms of colitis and restoring mucosal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sea buckthorn pulp oil.